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Epistasis and the Evolution of
Antimicrobial Resistance
Alex Wong*
Department of Biology, Carleton University, Ottawa, ON, Canada
The fitness effects of a mutation can depend, sometimes dramatically, on genetic
background; this phenomenon is often referred to as “epistasis.” Epistasis can have
important practical consequences in the context of antimicrobial resistance (AMR).
For example, genetic background plays an important role in determining the costs of
resistance, and hence in whether resistance will persist in the absence of antibiotic
pressure. Furthermore, interactions between resistance mutations can have important
implications for the evolution of multi-drug resistance. I argue that there is a need to
better characterize the extent and nature of epistasis for mutations and horizontally
transferred elements conferring AMR, particularly in clinical contexts. Furthermore, I
suggest that epistasis should be an important consideration in attempts to slow or limit
the evolution of AMR.
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INTRODUCTION
The same mutation, occurring in two different individuals, can have drastically different
consequences for phenotype and for fitness. A mutation’s effects may depend on the environment
in which an individual finds itself, or on the genetic background on which the mutation occurs. In
a classic example familiar from undergraduate genetics textbooks, the bw mutation causes a brown
eye phenotype in wild-type Drosophila melanogaster. However, the same bw mutation occurring
on a cn background (where the cn mutation usually causes a cinnabar eye color), results in a white-
eye phenotype. The microbial literature also abounds with examples of the importance of genetic
background. In any toxin-antitoxin system, the phenotypic effects of the presence of the toxin-
encoding gene are entirely dependent on genetic background: the toxin gene is lethal when the
antitoxin-encoding gene is absent, but not when it is present. The influences of genetic background
on a mutation’s effects are often referred to as “genetic interactions” or “epistasis,” and can have
profound implications for organismal fitness.
The study of epistasis has a long history in both theoretical and experimental biology
(e.g., Bateson, 1909; Wright, 1968; Cordell, 2002; Weinreich et al., 2005; Phillips, 2008). As a
consequence, there is a great deal of diversity – and sometimes confusion – with respect to the
terminology used to describe epistasis. In the current context, it is useful to consider epistasis in
terms of the fitness effects of two mutations alone, or in combination. Fitness is an organism’s ability
to survive and reproduce in a given environment, and in microbes fitness is often measured using
competitive assays (Melnyk et al., 2015), exponential growth rates in liquid culture, or colony sizes
on solid media. Formally, epistasis for fitness is defined as any situation in which the fitness of a
double mutant differs from what is expected given the fitness of the constituent single mutants. The
expected fitness is either the sum or the product of the single mutant fitness values, depending on
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the underlying model (Figure 1; see also Wade et al., 2001;
Chevin, 2011). In either case, epistasis is inferred if the realized
fitness of the double mutant is either higher or lower than
expected.
Amongst epistatic interactions, we can distinguish between
three varieties (Figure 2): (1) negative epistasis, whereby the
fitness of the double mutant is lower than expected, (2) positive
epistasis, whereby the fitness of the double mutant is higher than
expected, and (3) sign epistasis, whereby the sign of the fitness
of a mutation changes depending on genetic background – here,
a mutation may (for example) be deleterious on one genetic
background, but may be beneficial or have no effect on a different
genetic background (as is the case in toxin-antitoxin systems).
Reciprocal sign epistasis refers to cases whereby both members
of a pair of interacting mutations change their signs, such as
when two individually deleterious mutations become beneficial
in combination, or two individually beneficial mutations are
deleterious in combination.
Large-scale screens in Escherichia coli (Butland et al., 2008;
Typas et al., 2008; Babu et al., 2011, 2014) and yeasts (Roguev
FIGURE 1 | Null models for epistasis. The expected fitness of a double mutant can be calculated using either a multiplicative (A) or additive (B) model.
A multiplicative model is appropriate under a standard exponential growth model, with population size increasing according to λt (where t is time). (A) Shows
exponential growth curves for a hypothetical wild-type (black, λ = 2, indicating that population size doubles with each unit time), two mutants (orange, yellow, with λ
reduced by a factor of r and s, respectively), and the double mutant (blue). Note that the growth parameter λ of the double mutant is determined by the product of r
and s. An additive model is appropriate when population sizes are log-transformed, yielding a linear relationship between ln(population size) and time. (B) Shows
log-transformed growth curves for the same mutants as in (A). Note that the fitness of the double mutant is now determined by ln(r) + ln(s), where the log of the
population size at time t is given by eln(λ t).
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FIGURE 2 | Varieties of epistasis. Here, two mutations a and b are
individually deleterious with fitnesses of 0.8 and 0.6, respectively; the fitness of
the wild-type is 1 by definition. In the absence of epistasis, these mutations
combine multiplicatively, such that the fitness of the double mutant is the
product of their individual fitness values (0.48, dotted line). Under negative
epistasis, the fitness of the double mutant is lower than expected (here, 0.3).
Under positive epistasis, double mutant fitness is greater than expected
(0.54). The bar marked sign shows a situation whereby one mutation, a,
changes its sign when paired with b: on the wild-type background, a is
deleterious, but it is beneficial on the b mutant background (since the double
mutant, with a fitness of 0.7, is more fit than the b mutant alone). Finally, in the
case of reciprocal sign epistasis, both mutations switch their sign, becoming
beneficial in combination with a fitness of 1.2. Note that both of these cases of
sign epistasis are also cases of positive epistasis, since the double mutant
fitness is higher than expected.
et al., 2007; Costanzo et al., 2010) have shown that epistasis is
quite common. Such large-scale screens involve the construction
of hundreds of thousands to millions of double knockout mutant
combinations through the use of Hfr-mediated conjugation
(E. coli) or mating (yeast). Babu et al. (2011), for example,
investigated genetic interactions of genes involved in cell
envelope biogenesis in E. coli by measuring the colony sizes
of ∼350 000 double mutants. Remarkably, more than 54 000
genetic combinations were classified as epistatic in rich media,
and more than 38 000 were considered epistatic in minimal
media. These results suggest that epistasis is highly prevalent,
such that the effects of a mutation may depend strongly on
genetic background.
Epistasis has important implications for a wide range of
evolutionary phenomena, including speciation (Wade, 2002;
Presgraves, 2007), the evolution of sex (Charlesworth, 1990; Otto
and Michalakis, 1998), the trajectory of evolution (Weinreich
et al., 2006; Franke et al., 2011; Tenaillon et al., 2012),
and much else besides (Wolf et al., 2000). Here, I discuss
some of the implications of epistasis for the evolution and
management of antimicrobial resistance (AMR), with a primary
focus on pathogenic bacteria. Due to limitations in the published
literature, most of the examples used here refer to chromosomal
resistance mutations, rather than resistance elements harbored
on mobile genetic elements (MGEs) like plasmids and integrons.
Nonetheless, so far as data are available, many of the lessons
learned from chromosomal resistance mutations also apply to
MGEs; relevant examples are highlighted throughout. Because of
its potential importance, I suggest that epistasis should be given
greater consideration in the study of AMR. I argue that epistasis
may have important roles to play in determining the trajectory
of resistance evolution, in the persistence of costly resistance
mutations, and in the evolution of multi-drug resistance (MDR).
More positively, I suggest that we may in some instances be able
to leverage epistasis in efforts to counteract AMR.
THE EVOLUTIONARY TRAJECTORY OF
RESISTANCE ACQUISITION
Epistatic interactions can have important consequences for the
trajectory and tempo of adaptive evolution – that is, on what
mutations accrue during adaptation, in what order, and how
quickly. While much work in this area has not focused on AMR,
there are a number of studies in AMR that do address these issues.
In laboratory selection experiments, it is often observed that
fitness initially increases very rapidly, but that the rate of fitness
increase drops over time – later on during a selection experiment,
fitness increases at a much lower rate than during the early stages
(e.g., Elena and Lenski, 2003; Barrick et al., 2009; see also Couce
and Tenaillon, 2015). Several studies have shown that negative
epistasis between beneficial mutations underlies this pattern – it
appears that adaptive mutations, when combined, tend to have
a smaller beneficial effect than would be expected (Chou et al.,
2011; Khan et al., 2011; Schoustra et al., 2016); this pattern is
referred to as “diminishing returns epistasis.” Under diminishing
returns epistasis, an adapting population may accrue beneficial
mutations at a fairly steady rate even while fitness improves by
ever smaller steps (Barrick et al., 2009). Diminishing returns
epistasis suggests a clear prediction regarding the evolution of
AMR: when a bacterial population encounters a new drug, we
would expect the bulk of adaptation to occur early on, with
lower rates of adaptation as time passes. This prediction has
been confirmed experimentally for adaptation of Pseudomonas
aeruginosa to rifampicin (MacLean et al., 2010).
An additional consequence of epistasis – particularly sign
epistasis – is that it can limit the number of evolutionary
paths available to a population. Sign epistasis between mutations
that are individually advantageous may have profound effects
on the trajectory of evolution – if certain combinations of
advantageous mutations are deleterious, then we do not expect to
see these combinations persist. Such sign epistasis can constrain
the number of routes available to adaptation. The evolution
of classical β-lactamases into extended-spectrum β-lactamases
(ESBLs), capable of degrading cephalosporins, serves as a
striking example. Five mutations are required to convert a
classical β-lactamase into an ESBL, such that there are in
principle 120 possible routes to ESBL-activity. Weinreich et al.
(2006) constructed all 32 possible double mutants, and found
rampant sign epistasis, whereby many pairs of mutations showed
decreased fitness (i.e., reduced ability to degrade cephalosporins).
As a result, only 18 of the 120 possible evolutionary routes
are viable, insofar as they do not involve reductions in fitness.
A tempting conclusion, then, is that we might expect evolution to
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proceed in a repeatable manner – amongst the myriad of possible
ways to evolve ESBL-activity, only a handful will be realized.
However, many more evolutionary routes are available under
sub-MIC drug concentrations (Mira et al., 2015), indicating that
epistatic effects may be strongly environment-specific.
While the ESBL example suggests that epistasis can lead to
evolutionary convergence, at least under specific conditions, sign
epistasis can also lead to divergence between populations adapting
to the same environments. Populations of E. coli adapting to high
temperatures appear to adopt either of two mutually exclusive
metabolic solutions, one involving mutations in RNA polymerase
(rpoBC), and the other involving mutations in the termination
factor rho (Tenaillon et al., 2012). A number of mutations that
arise frequently on rpoBC mutant backgrounds are never seen on
rho mutant backgrounds, and vice versa, strongly suggesting sign
epistasis. Thus, once a population adopts – by chance – either the
rho or the rpoBC-mediated path to heat tolerance, it is committed
to a particular evolutionary trajectory, and will diverge from
populations adopting the alternative solution. There is little
evidence for similar patterns in the context of AMR, however;
several studies have suggested that populations adapting to
antibiotics tend to converge on similar genetic solutions (Vogwill
et al., 2014; Wong and Seguin, 2015).
EPISTASIS AND THE PERSISTENCE OF
AMR MUTATIONS
Many AMR mutations bear costs, insofar as they cause reduced
fitness in the absence of antibiotic (Cong et al., 2007; Andersson
and Hughes, 2010; Gerstein et al., 2012; Rosenthal, 2013; Vincent
et al., 2013; Melnyk et al., 2015; Vogwill and MacLean, 2015).
Melnyk et al. (2015) recently performed a meta-analysis of studies
that estimated the fitness of strains bearing defined, chromosomal
AMR mutations. Costs of resistance were widespread across
drug classes and bacterial species, although data were sparse. In
some cases (e.g., rifampicin, erythromycin), a single resistance
mutation results in a∼20% reduction in fitness under antibiotic-
free laboratory conditions, while in others (e.g., trimethoprim),
resistance is apparently cost-free. Fewer data are available for
resistance elements harbored on MGEs. However, a number of
studies have shown that carriage of plasmids or of other MGEs
is often costly (Lee and Edlin, 1985; Lenski and Bouma, 1987;
McDermott et al., 1993; Dahlberg and Chao, 2003; Enne et al.,
2004a, 2005; Dionisio et al., 2005; Heuer et al., 2007; Marciano
et al., 2007; Petersen et al., 2009; Starikova et al., 2012; Harms
et al., 2013; Starikova et al., 2013; San Millan et al., 2014b). In
a handful of cases, plasmid carriage has been shown to confer
a benefit, either on naïve or clinical genetic backgrounds (Enne
et al., 2004a), or in hosts that have co-evolved with a plasmid in
the laboratory (Bouma and Lenski, 1988; Dionisio et al., 2005;
Starikova et al., 2013). When plasmid carriage is costly, these
costs are typically associated with an entire element (plasmid,
transposon, etc. . .) potentially harboring many genes, and have
not been ascribed to a specific resistance gene per se. However,
costs associated with carriage of the non-conjugative pBR322
plasmid in E. coli are attributable to expression of its tetracycline
resistance gene (Lee and Edlin, 1985; Valenzuela et al., 1996),
and expression of the vancomycin resistance operon is required
for costs of VanB-mediated resistance in Enterococcus faecalis
(Foucault et al., 2010). More importantly, since transmissible
resistance genes are in fact associated with larger elements, fitness
of the entire element is arguably the more important parameter.
The widespread occurrence of costs of resistance points to the
possibility of controlling resistance through cessation of use of
a particular drug. For example, given that rifampicin resistance
typically carries a cost, we might expect that resistance should
decrease in frequency in clinical populations if use of rifampicin
(and related compounds) were to be stopped. Interestingly,
cessation of use has mixed results in mitigating AMR (Costelloe
et al., 2010; Enne, 2010). Notably, in several cases, resistance has
persisted for months or years despite a substantial reduction in
prescription (Sundqvist et al., 2010).
There are several possible explanations for the persistence
of costly AMR alleles in the absence of antibiotic (Enne, 2010;
Melnyk et al., 2015). Some AMR elements may be cost-free,
either universally or in specific environments (Humphrey et al.,
2012; Gifford et al., 2016), while AMR elements on plasmids
may be maintained via co-selection for other plasmid-encoded
functions (Pal et al., 2015). When an AMR mutation is initially
costly, those costs may be reduced or eliminated by compensatory
mutations – that is, mutations that increase fitness without
eliminating resistance. The term “compensatory” is sometimes
reserved for fitness-restoring mutations that occur after an
initial resistance mutation. However, in terms of fitness effects,
it is irrelevant whether a second-site mutation occurs prior
to, or after, the resistance mutation for which it compensates
(although second-site mutations that are deleterious on a drug
sensitive background are unlikely to segregate independently of
the resistance mutation; Schrag et al., 1997). As such, I here
refer to as compensatory any mutation that restores fitness costs
imposed by a resistance mutation (Figure 3), regardless of when
it arises.
In demonstrating the effects of genetic background on the
fitness of resistance mutations, it is worth noting that laboratory
measurements of the fitness of AMR mutations are almost
always limited to a single genetic background: A resistance
mutation is introduced onto a single “wild-type” background –
typically a standard lab strain such as E. coli K-12 – and
fitness is measured by competing this defined mutant against
the wild-type control. However, a particular AMR mutation
may or may not impose the same costs on different genetic
backgrounds. In Campylobacter jejuni, costs associated with the
gyrA C257T mutation, which confers fluoroquinolone resistance
(FQR), are strongly dependent on genetic background (Luo et al.,
2005). On one genetic background, the FQR allele outcompetes
the FQS allele in a chicken model of infection, whereas the
FQS allele outcompetes the FQR allele on a different genetic
background, indicating the presence of genetic modifiers – that
is, compensatory mutations – elsewhere in the genome. Similar
patterns, whereby the fitness effect of an AMR mutation varies
with genetic background, have also been described for rifampicin
resistance in P. aeruginosa (MacLean et al., 2010) and Bacillus
subtilis (Cohan et al., 1994), and for clarithromycin resistance
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FIGURE 3 | Alleviation of the costs of antibiotic resistance by compensatory mutations. (A) A drug susceptible genotype (open circle) experiences an
antimicrobial resistance (AMR) mutation (closed circle), which reduces its fitness in the absence of antibiotic. Wild-type fitness is given by the dotted line. (B) A drug
susceptible genotype (open circle) experiences an AMR mutation (closed circle), which reduces its fitness in the absence of antibiotic. This genotype subsequently
sustains a compensatory mutation which restores fitness but does not eliminate resistance (close triangle). Here, a compensatory mutation arises after the costly
AMR mutation. While the compensatory mutation is here depicted as neutral, such mutations may impose a fitness cost on the drug sensitive background (Schrag
et al., 1997; Brandis et al., 2012). (C) Compensatory mutations that do not themselves carry a cost may also precede the AMR mutation. Here, a drug susceptible
genotype experiences a mutation (open triangle) that does not affect fitness, but which later alleviates the fitness deficit that would have been imposed by the AMR
mutation (closed triangle).
in Helicobacter pylori (Björkholm et al., 2001). The few available
data suggest that genetic background can also influence the fitness
of MGEs. For example, the conjugative plasmid RP1 was found
to impose fitness costs in a laboratory strain, as well as in two
clinical isolates, of E. coli, but not in two strains isolated from pig
feces (Humphrey et al., 2012; see also Enne et al., 2004a; Starikova
et al., 2013; Di Luca et al., 2017).
Compensatory evolution has been proposed as an important
mechanism for the persistence of AMR strains in the absence
of antibiotics (Andersson, 2003, 2006; Melnyk et al., 2015, but
see MacLean and Vogwill, 2014 for a different perspective). In
vitro selection experiments, whereby populations bearing a costly
resistance mutation are passaged in a drug-free environment,
have shown that compensatory evolution occurs readily in the
laboratory for a wide range of resistance elements and bacterial
species (for chromosomal mutations, see Schrag and Perrot,
1996; Bjorkman et al., 2000; Reynolds, 2000; Nagaev et al., 2001;
Maisnier-Patin et al., 2002; Enne et al., 2004b; Kugelberg et al.,
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2005; Maisnier-Patin et al., 2007; Paulander et al., 2007; Brandis
et al., 2012; Hall, 2013; Knopp and Andersson, 2015; Qi et al.,
2016; for MGEs see Helling et al., 1981; Bouma and Lenski,
1988; McDermott et al., 1993; Dahlberg and Chao, 2003; Dionisio
et al., 2005; Heuer et al., 2007; Starikova et al., 2013; San Millan
et al., 2014b). Thus, for any given resistance mutation, there
may be many available compensatory mutations. In some cases,
compensation has been observed between pairs of resistance
mutations for the same drug – for example, individually costly
RifR mutations in P. aeruginosa can compensate for each other
(Hall and MacLean, 2011, see also Rozen et al., 2007), leading to
both increased fitness and increased drug resistance. Importantly,
in in vitro compensation experiments, reversion of resistance
mutations is rare relative to second-site mutations conferring
fitness benefits (putative compensatory mutations; Hughes and
Andersson, 2015), implying that resistant genotypes are likely
to regain fitness in a drug-free environment without losing
resistance.
The mechanisms underlying compensation have been
described in several cases, and often involve restoring processes
that are disrupted by the initial resistance mutation (for broader
discussions of the mechanisms of epistasis see Boone et al., 2007;
de Visser et al., 2011). Knopp and Andersson (2015), for example,
investigated mechanisms of compensation in ompCF double
mutants of E. coli. ompC and ompF encode outer membrane
porins by which a number of antibiotics, including carbapenems,
gain access to the periplasm. Mutations in these proteins confer
modest- to high-levels of carbapenem resistance (fourfold for
meropenem, 60-fold for ertapenem), but with an associated cost
(∼15% in this study). After 250 generations of in vitro selection,
fitness was recovered to between 89 and 99% of the wild-type,
with carbapenem resistance maintained in some cases and lost in
others. Subsequent analyses showed that compensation occurred
via over-expression of the alternative porins PhoE or ChiP,
which presumably replaced important physiological functions of
OmpCF.
Restoration of normal cellular functions is also implicated in
compensation for costs associated with disrupted transcription
and translation. In many bacteria, mutations in rpoB, which
encodes the β-subunit of RNA polymerase, are known to cause
high levels of rifampicin resistance, typically with an associated
fitness cost. In laboratory experiments using Salmonella enterica,
compensation consistently occurs via mutations in rpoA, rpoB,
and rpoC (Brandis et al., 2012), where rpoA and rpoC
encode additional subunits of RNA polymerase. Structural
considerations suggest that these compensatory mutations
improve deleterious effects of the rpoB R529C mutation on rates
of transcription, for example by improving RNA stability or by
affecting the structure of the exit channel in which residue 529 is
located (Brandis et al., 2012). Similarly, Schrag and Perrot (1996)
found that protein elongation rates were reduced in streptomycin
resistant rpsL mutants of E. coli, and that elongation rates were
increased following compensatory evolution.
Less is known concerning the mechanisms underlying
compensation for costs associated with plasmids and other
MGEs. Several older studies suggested that compensatory
mutations were to be found on the host chromosome, rather
than on the plasmid (Helling et al., 1981; Bouma and Lenski,
1988). More recently, sequencing has corroborated these results
in P. aeruginosa (San Millan et al., 2014b), where carriage of the
costly plasmid pNUK73 was compensated following laboratory
selection experiments. In six compensated clones, no mutations
were found on pNUK73, but each carried a mutation in either
of two chromosomal genes, one encoding a putative helicase,
and the other encoding a putative protein kinase. Mutations
in both genes were shown to reduce segregational loss of
the plasmid, although the precise mechanism underlying this
increased stability has yet to be elucidated.
While it is clear that compensatory evolution occurs readily
in the laboratory, the clinical and epidemiological importance
of compensation is still unclear. For example, in the absence
of antibiotic, resistant strains may be outcompeted by resident
sensitive strains before compensation occurs (MacLean and
Vogwill, 2014, but see Gifford and MacLean, 2013). We simply
have little data on the frequency of compensatory evolution
in patient populations. Nonetheless, there is good evidence for
clinically relevant compensatory evolution in rifampicin resistant
strains of Mycobacterium tuberculosis. Mutations in rpoA, rpoB,
and rpoC, similar to those implicated in compensatory evolution
in S. enterica, have been identified in RifR – but not in RifS –
clinical isolates of M. tuberculosis in several studies (Cohen et al.,
2015; Coscolla et al., 2015), consistent with compensation in a
clinical setting. Moreover, rpoB mutations bearing a high cost
in Salmonella are more likely to be associated with putative
compensatory mutations in M. tuberculosis (Brandis et al., 2015),
again suggesting an important role for compensation. Overall,
however, there is a need to further investigate the contribution
of compensatory evolution to the persistence of AMR in clinical
settings; this could be accomplished by screening clinical strains
for compensatory mutations known from laboratory studies.
Interactions between AMR mutations and compensatory
mutations are typically conceived of as sign epistatic, whereby the
AMR mutation is deleterious on some backgrounds, but neutral
or advantageous on others. Brandis et al. (2012), for example,
measured growth rates for 10 mutations that compensate for
fitness deficits in rifampicin resistant mutants of S. enterica. Each
of these mutations, which were found in rpoA or rpoC, partially
or completely restored growth defects caused by the rpoB R529C
resistance mutation. However, in isolation, the compensatory
mutations were either deleterious or had no effect on growth
rates. These mutations were thus beneficial on the resistant
background but not on the wild-type background, fulfilling the
definition of sign epistasis. Interestingly, the persistence of a
resistance mutation is promoted when compensatory mutations
are deleterious on the drug sensitive background: reversion
mutations are selected against, since reversion simply generates
the drug sensitive background with the compensatory mutation
(Schrag et al., 1997).
While there are a number of documented cases of sign
epistasis between resistance mutations and compensatory
mutations, there is a certain amount of ambiguity as to whether
sign epistasis is a necessary condition for considering a mutation
to be compensatory. For example, what are we to make of a
candidate compensatory mutation that is equally beneficial on
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both resistant and susceptible backgrounds? Or of a mutation
that is beneficial on resistant and susceptible backgrounds, but
more beneficial on the resistant background (a case of positive
epistasis)? Neither of these cases meets the strict definition of
sign epistasis, but could nonetheless contribute to the persistence
of AMR alleles in pathogen populations. It is not my intent to
resolve this semantic issue here, but rather simply to point out
the potential for conceptual ambiguity.
EPISTASIS AND THE EVOLUTION OF
MULTI-DRUG RESISTANCE
Multi-drug resistance typically involves the accumulation of
multiple resistance mutations and/or plasmid-borne resistance
elements; alternatively, single mutations affecting eﬄux or
permeability can cause MDR, but typically at lower levels
than multiple-mutation driven MDR (reviewed in Chang et al.,
2015). There is thus ample opportunity for genetic interactions
between chromosomal mutations, between plasmids, or between
chromosomal mutations and plasmids, in the evolution of MDR.
The nature of such genetic interactions may be an important
factor in the persistence of MDR strains. Consider, for example,
a case where two individual resistance mutations are costly –
that is, they are each less fit than susceptible competitors in
the absence of drug. If the double mutant is less fit than either
single mutant (no epistasis or negative epistasis), then it will be
outcompeted by the single mutants and by susceptible strains.
Alternatively, if the double mutant is more fit than at least
one of the single mutants (positive sign epistasis), then it is
expected to at least outcompete that single mutant. In the most
extreme case, the double mutant may be as fit, or more fit, than
susceptible competitors, in which case the MDR strain is expected
to outcompete even susceptible strains in the absence of drug.
Studies across a range of bacterial species and resistance
mechanisms have revealed widespread positive epistasis with
respect to fitness in the absence of drug, including cases where the
fitness of MDR strains equals or exceeds susceptible competitors
(Trindade et al., 2009; Ward et al., 2009; Angst and Hall,
2013; Borrell et al., 2013; Durao et al., 2015). For example,
Trindade et al. (2009) examined epistasis between mutations
in rpoB, rpsL (streptomycin resistance), and gyrA (quinolone
resistance) in E. coli. Epistasis was detected for more than half
of the 103 double mutants, and 73% of cases of epistasis were
positive, i.e., double mutant fitness was higher than expected.
Double mutant fitness was equal to or greater than that of the
isogenic susceptible control in six cases; these genotypes might be
expected to be particularly common in clinical settings, at least
insofar as laboratory fitness estimates are predictive of fitness
in patients. Similarly, positive epistasis has been documented
between chromosomal resistance mutations and conjugative
plasmids (Silva et al., 2011), and between pairs of plasmids (San
Millan et al., 2014a). By contrast, a recent study found that genes
present on a chromosomally integrated MGEs were responsible
for reductions in plasmid fitness in P. aeruginosa (San Millan
et al., 2015); in this case, negative epistatic interactions might be
expected to limit evolution by horizontal transfer.
Widespread positive epistasis between resistance mutations in
different genes contrasts sharply with recent studies on intragenic
epistasis, where negative epistasis predominates (Bank et al.,
2015; Li et al., 2016; Puchta et al., 2016; Sarkisyan et al., 2016).
Bank et al. (2015), for example, estimated fitness for more than
1000 double mutants (and their corresponding single mutants)
of the yeast heat shock protein Hsp90. Almost half of the double
mutants showed negative epistasis, while positive epistasis was
observed in only 1.8% of cases. The reasons underlying this
difference in the distribution of epistatic effects are unclear. For
example, this distribution may differ for intragenic and extragenic
mutation pairs, due to the nature of functional interactions
between these mutations – consistent with this hypothesis,
positive and negative epistasis are roughly equally prevalent for
transposon insertions in E. coli (Elena and Lenski, 1997). Further
empirical and theoretical work is needed to clarify this issue.
There is limited but compelling evidence that positive epistasis
drives the evolution of MDR in clinical settings. Borrell et al.
(2013) measured the fitness of 17 genotypes of Mycobacterium
smegmatis resistant to both rifampicin and ofloxacin, as well as
of the constituent single rpoB and gyrA mutants. Notably, the
gyrA D94G mutation was associated with fitness increases for
all five rpoB alleles that were tested, whereas the gyrA G88C
allele was associated with reduced fitness. Correspondingly, in a
sample of 151 MDR and XDR (extensively drug resistant) clinical
isolates of M. tuberculosis (that are, by definition, resistant to
both rifampicin and ofloxacin), 71 bore the D94G allele, while
the G88C allele was present in only one. Together, these results
suggest that positive epistatic interactions between gyrA D94G
and rpoB mutations favor the survival of genotypes bearing
D94G. Nonetheless, more data are needed on the distribution
of resistance alleles in clinical isolates to make broad inferences
about the impact of epistasis in maintaining MDR.
MANAGEMENT OF AMR: CLUES FROM
EPISTASIS
As discussed in the previous two sections, laboratory
experiments – and to a lesser extent studies of clinical isolates –
suggest important roles for epistasis in maintaining single- and
multi-drug resistance, thus increasing the challenges associated
with tackling AMR. More optimistically, there are opportunities
to leverage epistasis in the management of AMR.
Knowledge of the epistatic interactions of resistance mutations
should help to inform decisions as to which drug combinations to
deploy in clinical settings. Drug combinations are often chosen
to maximize the rate of clearance. In particular, synergistic
drug combinations – whereby the combined inhibitory effect of
two drugs is stronger than expected – are often preferred for
their ability to clear infections. However, the use of synergistic
drug combinations also increases selection on resistance alleles,
since resistance to one drug also alleviates the synergistic
effects. Consequently, the use of synergistic drug combinations
can promote the evolution of resistance, at least under some
conditions (Hegreness et al., 2008; Michel et al., 2008; Torella
et al., 2010). Thus, it has been suggested that the primary goal
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of multi-drug therapy should be to slow or prevent the evolution
of resistance (Chait et al., 2007; Yeh et al., 2009; Imamovic and
Sommer, 2013; Palmer and Kishony, 2013; Bollenbach, 2015;
Baym et al., 2016), rather than to clear infections quickly.
Knowledge of the epistatic interactions of resistance mutations
can and should inform such efforts to minimize the evolution of
AMR via multi-drug therapy. There are several ways in which
epistasis is relevant. First, negative epistasis between resistance
mutations might be leveraged to counteract the evolution of
MDR in clinical populations. In some cases, pairs of resistance
mutations interact negatively – that is, the fitness of the double
mutant is lower than expected given the fitness of the single
mutants. As such, genotypes resistant to both drugs have highly
reduced fitness, and are expected to be outcompeted by single-
resistant and susceptible genotypes. Thus, it has been proposed
that we should employ pairs of antibiotics for which there is
negative epistasis between resistance mutations (Muller et al.,
2013).
Cases of negative epistasis have indeed been documented for
particular pairs of resistance alleles. For example, Trindade et al.
(2009) found strongly negative epistasis between K43T mutations
in rpsL and D87G mutations in gyrA in E. coli. Unfortunately,
other pairs of quinolone- and streptomycin-resistance conferring
mutations show no epistasis or positive epistasis, e.g., rpsL
K43R and gyrA D87G. Thus, in clinical samples resistant to
both streptomycin and quinolones, we might expect to see an
excess of K43R/D87G genotypes and a deficit of K43T/D87G
genotypes. However, an overall reduction in the frequency of
doubly-resistant genotypes is not necessarily expected. Indeed,
this example highlights the fact that reducing the prevalence of
MDR genotypes requires negative interactions between most or
all possible resistance mutations at two (or more) loci. If some
pairs of resistance mutations have relatively high fitness, then
multi-drug treatment will simply select for those pairs. Such
systematic negative epistasis between sets of resistance mutations
has not been documented; there instead seems to be a great deal
of allele-specificity in genetic interactions (Trindade et al., 2009).
Nonetheless, genetic interactions between AMR mutations have
simply not been investigated for the majority of drugs, nor in the
majority of pathogens, so we cannot rule out the plausibility of
the approach.
Another approach to counteracting the evolution of AMR
is to take advantage of the collateral drug sensitivity imposed
by some resistance mutations (e.g., Imamovic and Sommer,
2013; Lazar et al., 2013; Munck et al., 2014; Oz et al., 2014).
Certain resistance mutations confer increased sensitivity to
other drugs. Such mutations are, therefore, pleiotropic, insofar
as they affect traits other than the one for which they were
selected. For example, aminoglycoside resistance is frequently
accompanied by increased sensitivity to multiple drug classes,
including quinolones, tetracyclines, and β-lactams (Imamovic
and Sommer, 2013; Lazar et al., 2013; Oz et al., 2014).
Reductions in proton-motive force (PMF), which confer low-
level aminoglycoside resistance, are thought to underlie this
collateral sensitivity (Lazar et al., 2013). The existence of
collateral sensitivity suggests the use of co-dosing regimens
informed by knowledge of collateral sensitivities – co-dosing
between an aminoglycoside and a quinolone might, for example,
slow the emergence of aminoglycoside resistance. Laboratory
selection experiments confirm the potential to slow the evolution
of resistance by leveraging collateral sensitivity (Kim et al.,
2014). Populations of Staphylococcus aureus were evolved
under mixed- or alternating treatments of pairs of drugs.
Resistance evolution was generally slowed compared to single-
drug controls, and patterns of collateral sensitivity predicted the
outcomes. For example, most single-step trimethoprim-resistant
mutants of S. aureus were collaterally sensitive to ciprofloxacin.
Correspondingly, the acquisition of trimethoprim resistance was
slowed in mixed trimethoprim-ciprofloxacin treatments.
Typically, collateral sensitivities are identified using chemical-
genetic approaches, whereby MICs are determined for a wide
range of known antibiotics against a set of AMR genotypes
(Imamovic and Sommer, 2013; Lazar et al., 2013). Similarly,
novel screening approaches have been developed to identify
microbially derived compounds that are particularly effective
against AMR strains (Chait et al., 2010). Genetic interaction
screens may be a useful complement in identifying collateral
sensitivities. For example, if a particular AMR mutant were to
show negative interactions with knockouts in a number of cell
wall genes, then this would suggest that drugs targeting the
cell wall (e.g., β-lactams, fosfomycin) might select against that
AMR mutation. Moreover, such screens might identify novel
drug targets that interact negatively with an AMR mutation,
with no currently available antibiotic for that target. To date,
large-scale genetic interaction screens have not included many
AMR mutations; chromosomal AMR mutations are often point
mutations in essential genes, and essential genes are by definition
not included in the knockout collections employed in most
large-scale strategies. There is thus a need to expand large-scale
screens to include point mutants as “baits,” in order to uncover
mutations that interact with the specific mutations underlying
AMR. Indeed, the success of genetic interaction screens in
identifying novel drug targets specific to cancer cells provides
promise for this approach in combatting AMR (Hartwell et al.,
1997; Kaelin, 2005; Shaheen et al., 2011).
While these examples suggest that knowledge of the genetic
interactions of AMR mutations can inform efforts to manage
resistance, a word of warning is in order. These approaches all
aim to maximize the costs of resistance, either in the absence of
drugs, or, in the case of collateral sensitivity, in the presence of
specific antibiotics. While maximization of the cost of resistance
is clearly an admirable goal, it too has its drawbacks. As illustrated
earlier in this manuscript, compensatory evolution occurs
rapidly and easily; moreover, low-fitness (high cost) genotypes
compensate more quickly than higher-fitness genotypes (Moore
et al., 2000; Gifford et al., 2011). Thus, unless high-cost genotypes
are eliminated very quickly from a population, we should expect
that they too will persist due to compensatory evolution.
CONCLUSION
Epistasis is a widespread phenomenon, with 10s–100s of 1000s
of genetic interactions identified in large-scale screens in model
Frontiers in Microbiology | www.frontiersin.org 8 February 2017 | Volume 8 | Article 246
fmicb-08-00246 February 15, 2017 Time: 13:30 # 9
Wong Epistasis and the Evolution of AMR
microbes (Butland et al., 2008; Typas et al., 2008; Costanzo et al.,
2010). The epistatic interactions of AMR mutations may play
important roles in the persistence of resistance, via compensatory
evolution, and in the evolution of MDR, due to positive
epistasis between different resistance mutations. Moreover, an
understanding of the epistatic interactions of AMR mutations
would be helpful in developing strategies – and therapeutic
agents – for mitigating the evolution of resistance.
Given the importance of epistasis in the evolution and
management of AMR, broader efforts are needed to fully
characterize the genetic interactions of AMR mutations. Large-
scale screens measuring the fitness of AMR mutants in
combination with genome-wide knockout libraries, or with
over-expression constructs, will be valuable tools in this effort.
Moreover, laboratory selection experiments can yield important
information on epistatic interactions. Here, replicate populations
are passaged for 10s–1000s of generations under defined
conditions in the laboratory, and whole-genome sequencing
can be used to identify adaptive mutations that have arisen
over the course of selection. Epistasis can be inferred from
patterns of co-occurrence, or lack thereof, between mutations.
For example, following 150 generations of selection in sub-
inhibitory concentrations of ciprofloxacin, we found that a given
genotype would bear a mutation in either gyrA or gyrB (the
genes encoding DNA gyrase, the target of ciprofloxacin), but
never in both (Wong and Seguin, 2015). This result suggests
that, under the selection conditions, mutations in gyrA or gyrB
were individually adaptive, but that double mutants gained
no additional benefit – indicating negative epistasis between
mutations in these two genes.
There are relatively few data concerning the genetic
interactions of plasmids or other MGEs. The available evidence
suggests that certain broad patterns may be shared between
chromosomal mutations and plasmids. Fitness costs are
associated with both, although both chromosomal mutations
and MGEs may be cost-free or even advantageous in the
absence of drug. In both cases, positive epistasis may play
an important role in reducing fitness costs where they
are present. Nonetheless, given the critical importance of
horizontally transferred resistance, for example for β-lactams
and aminoglycosides (e.g., Davies, 1994), much more effort
is required to characterize the genetic interactions of MGEs.
Moreover, theoretical and empirical investigations will help
to determine the contribution of epistasis to the persistence
of MGEs, as opposed to other factors such as co-selection or
spatially variable selection.
Similarly, there are few data concerning the genetic
interactions of eﬄux mutations, despite the importance of
eﬄux in MDR in a variety of pathogens (Vila et al., 2007;
Vila and Martinez, 2008; Hirsch and Tam, 2010; Wong and
Kassen, 2011). Mutations that increase eﬄux pump expression
are sometimes, but not always, costly in in vitro assays
(Alonso et al., 2004; Stickland et al., 2010; Olivares et al.,
2012), and have been shown to negatively impact virulence
in P. aeruginosa (Olivares et al., 2012) and Stenotrophomonas
maltophilia (Alonso et al., 2004). However, the interactions of
eﬄux mutations with other resistance mutations, as well as
mechanisms of compensation for costly eﬄux mutations, remain
to be investigated.
Finally, as suggested throughout this review, more work
is needed to determine the impact of epistasis in clinical
pathogen populations. With the advent of rapid, cost-effective
whole-genome sequencing, we can search the genomes of
clinical isolates for compensatory mutations identified in the
laboratory (Cohen et al., 2015; Coscolla et al., 2015). Similarly,
we might predict that pairs of resistance elements that show
positive epistasis should be over-represented in clinical MDR
strains. Such data will help us to determine the importance
of epistasis in the evolution of clinical pathogen populations,
and will in turn inform efforts to mitigate the evolution of
resistance.
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